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Abstract
Leishmaniasis is a major health problem to humans and is caused by one of the world’s major pathogens, the Leishmania
parasite. These protozoa have the remarkable ability to avoid destruction in hostile environments they encounter throughout
their life cycle. That Leishmania parasites have adapted to not only survive, but to proliferate largely is due to the protection
conferred by unique glycoconjugates that are either on the parasites’ cell surface or secreted. Most of these specialized
molecules are members of a family of phosphoglycans while others are a family of glycosylinositol phospholipids. Together
they have been implicated in a surprisingly large number of functions for the parasites throughout their life cycle and,
therefore, are key players in their pathogenesis. This review summarizes the biological roles of these glycoconjugates and how
they are believed to contribute to Leishmania survival in destructive surroundings. ß 1999 Elsevier Science B.V. All rights
reserved.
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1. Leishmaniasis
Protozoan parasites of the genus Leishmania are
members of the family Trypanosomatidae, which
comprises unicellular organisms characterized by
the presence of a single £agellum and of a DNA-
rich, mitochondria-like organelle, the kinetoplast.
The various species of the genus Leishmania infect
millions of people worldwide, causing a wide spec-
trum of diseases collectively termed leishmaniases
that vary in their clinical manifestations and symp-
toms. Cutaneous leishmaniasis, an infection charac-
terized by the apparition of ulcerative lesions of the
skin, is principally caused by Leishmania major,
Leishmania tropica, and Leishmania mexicana.
Although in some cases lesions will persist and dis-
seminate, cutaneous leishmaniasis is generally a self-
healing disease. A variant form of cutaneous leish-
maniasis, called mucocutaneous leishmaniasis, is
caused by Leishmania braziliensis braziliensis. This
parasite has a tropism for macrophages of the oro-
naso-pharyngeal region, were it produces a mucosal
granuloma that eventually destroys the nose and
mouth. Visceral leishmaniasis, also known as Kala-
azar, represents the most severe clinical manifesta-
tion of Leishmania infection. The causative agent,
Leishmania donovanii, disseminates and infects mac-
rophages of the liver, the spleen, and the bone mar-
row. This infection is chronic and may be fatal in
untreated cases. E⁄cient prophylactic measures, in-
cluding safe vaccines, are currently not available and
the success of chemotherapeutic treatments, which
rely on toxic antimonial drugs or diamidine com-
pounds, is threatened by the spread of drug resist-
ance.
2. The life cycle of Leishmania
During its life cycle, the parasite Leishmania alter-
nates between two distinct developmental stages. In
the mammalian host, the parasite exists under the
non-motile amastigote form, which proliferates with-
in the acidic and hydrolase-rich phagolysosomal
compartment of host macrophages [1]. Transmission
of the parasite is mediated by the blood-sucking sand
£y, of either the genus Phlebotomus (in the Old
World) or the genus Lutzomyia (in the New World).
When feeding on an infected mammal, the sand £y
takes up amastigote-containing macrophages/mono-
cytes. During digestion of the bloodmeal, amasti-
gotes initiate their di¡erentiation into the motile pro-
mastigote form, which will attach to the midgut
epithelium to avoid being excreted together with
the digested bloodmeal. Virulence is acquired during
metacyclogenesis, a process by which dividing, non-
infective promastigotes (procyclic) transform into a
non-dividing infective form [2]. These metacyclic pro-
mastigotes detach from the gut epithelial cells and
migrate towards the anterior end of the digestive
tract. Upon the next bloodmeal, metacyclic promas-
tigotes are inoculated into the mammalian host,
where they must successfully evade and resist non-
speci¢c defense mechanisms such as complement-
mediated lysis, to ultimately bind and enter mono-
nuclear phagocytes by a receptor-mediated process.
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Once inside a parasitophorous vacuole or phago-
some, metacyclic promastigotes avoid degradation
and establish conditions favorable to their prolifera-
tion. The increased temperature and the decreased
phagosomal pH provide the signals required for the
promastigote-to-amastigote di¡erentiation [3]. Ulti-
mately, infected macrophages rupture, releasing the
amastigotes into the surrounding environment where
they can infect neighboring macrophages.
To understand the critical signi¢cance of glycocon-
jugates in Leishmania biology, it is important to in-
vestigate how the parasite is able to survive harsh
environments in its life cycle. The parasite must
avoid destruction in (i) the sand £y midgut where
the parasite could be vulnerable to a variety of di-
gestive enzymes, (ii) the bloodstream of the host
where the organism transiently exists and would be
exposed to the lytic complement pathway, and most
spectacularly (iii) the phagolysosome of host macro-
phages where the parasite would be exposed to a
number of hydrolytic enzymes, acidic pH, and the
microbiocidal oxidative burst. Elucidating the molec-
ular details of how this pathogen survives in obvi-
ously hostile environments involves a thorough
understanding of the structure, biosynthesis, and
function of glycoconjugates throughout its existence.
3. Major Leishmania glycoconjugates
3.1. Lipophosphoglycan
The major surface glycoconjugate of all Leishma-
nia promastigotes is a unique molecule called lipo-
phosphoglycan (LPG). The structure of LPG from
diverse Leishmania species has been determined and
the organization of its four domains is best illus-
trated by the prototypic L. donovanii LPG in Fig.
2. The four domains of the L. donovanii LPG are
(i) a 1-O-alkyl-2-lyso-phosphatidyl(myo)inositol an-
chor, (ii) a glycan core, (iii) repeating disaccharide
phosphate units, and (iv) a small oligosaccharide
cap. LPG from all species of Leishmania have an
identical lipid anchor and glycan core [4,5]. The
Gal-Man-PO4 backbone of the repeating units is
also conserved, but the LPGs from other species of
Leishmania can have additional sugars branching o¡
the backbone sugars. There can also be minor varia-
tions in cap structure.
LPG undergoes several important modi¢cations
during the life cycle that are characteristic for each
Leishmania species. During the process of metacyclo-
genesis [2,6] of L. donovanii, in which the promasti-
gotes convert from non-infectious to highly infec-
tious forms, LPG undergoes elongation due to an
approximate doubling in the number of repeating
units, from about 15 in procyclic promastigotes to
about 30 in metacyclic forms [7]. In other species,
substitutions to the repeating units often occur
[8,9]. These changes play important roles in the bind-
Fig. 1. Life cycle of Leishmania.
Fig. 2. Structure of LPG from L. donovanii. Galf , galactofuranose; P, phosphate.
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ing and release of the parasite from the sand £y
midgut (discussed below) [9,10]. While LPG is abun-
dantly present on the surface of promastigotes, it is
down-regulated in the amastigote stage by at least
three orders of magnitude [11,12]. Additionally, the
LPG synthesized in amastigotes frequently di¡ers in
structure from that of the promastigote [11,13].
3.2. Surface or secreted molecules bearing domains
related to LPG
All of the domains of LPG appear as components
of other parasite glycoconjugates [14] (Fig. 3). The
surface protease gp63 is anchored by a GPI anchor
[15]. The secreted acid phosphatase (sAP) and a se-
creted mucin-like proteophosphoglycan (PPG) both
bear disaccharide phosphate repeating units and cap-
ping structures [16^19]; sAP additionally bears typi-
cal N-linked oligosaccharides. The secreted extracel-
lular phosphoglycan (PG, formerly ‘excreted factor’)
consists exclusively of a polymer of disaccharide
phosphate repeating units bearing LPG-like capping
sugars [20]. Lastly, a family of small and structurally
related glycosylinositol phospholipids (GIPLs) is
present at high levels in both promastigotes and
amastigotes. GIPLs vary in sugar and lipid compo-
sitions; some GIPLs are precursors of LPG or pro-
tein GPI anchors, whereas others are distinct surface
entities [5,21].
Thus, virtually every known surface molecule as
well as some secreted glycoconjugates of this parasite
show some intersection with the LPG biosynthetic
pathway, especially in the synthesis of the repeat-
ing units and GPI anchors. This underscores the im-
portance of these structures to the parasite’s surviv-
al.
4. Glycoconjugates in sand £y-Leishmania
interactions
4.1. Overview
Procyclic promastigotes exhibit an inherent ca-
pacity to attach to midgut epithelial cells, which en-
ables the parasite to persist in the gut during excre-
tion of the digested bloodmeal (Fig. 1). In contrast,
metacyclic promastigotes lose this capacity, thereby
permitting the detachment and anterior migration of
infective forms so that they can be transmitted dur-
ing a subsequent bloodmeal. Metacyclic promasti-
gotes are well adapted for both arrival at and surviv-
al in the vertebrate host. Thus, the ability of
Leishmania to bind to the midgut of their phleboto-
mine vectors during excretion of the digested blood-
meal is essential for the development of transmissible
infections. Understanding the basis of these molecu-
lar interactions is fundamental to investigating vector
Fig. 3. Types of Leishmania molecules containing LPG domains. PI, phosphatidylinositol ; GIPL, glycosylinositol phospholipids; PG,
extracellular phosphoglycan; sAP, secreted phosphoglycan; PPG, proteophosphoglycan; EthN, phosphoethanolamine. In LPG the an-
chor is 1-O-alkyl-2-lyso-PI compared to 1-O-alkyl-2-acyl-PI in GIPLs and GPI-anchored proteins. The glycan cores in LPG, GIPLs
and GPI-anchored proteins vary in structure, but all have the conserved Man(K1,4)GlcN(K1,6)-myo-inositol motif that is characteristic
of GPI-anchored molecules.
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competence and disease transmission. Sand £y vec-
tors can, in some instances, transmit only certain
species of Leishmania. Such species-speci¢c di¡eren-
ces in vectorial competence have been directly corre-
lated with the ability of promastigotes to attach to
the sand £y midgut, the variable outcomes of which
are controlled by structural polymorphisms in LPG
[10].
4.2. L. major-sand £y interactions
Evidence that LPG plays a substantial role in
metacyclic virulence was ¢rst described based on a
series of studies with L. major [22]. Procyclic L. ma-
jor promastigotes express an LPG that is character-
ized by mono- or di-L1,4-galactose side chain substi-
tutions that branch o¡ the 3-OH of the galactose
residues in the repeating units [23,24] (Fig. 1). A
L1,3-galactosyltransferase involved in synthesis of
these side chain galactose residues has recently been
described [24]. As in all procyclic forms, the number
of repeating units in the L. major LPG is approx. 15
[23]. Studies have shown that the natural vector,
Phlebotomine papatasi, possesses a L-galactose-bind-
ing lectin in its midgut that recognizes the terminal L-
linked galactose residues of the L. major LPG
[9,25,26]. LPG enables the attachment of the parasite
to the midgut lectin after a few days following inges-
tion of a bloodmeal and also confers protection from
digestive enzymes. While the parasite is attached, the
digested blood meal is excreted. Gut-associated lec-
tins or lectin-like molecules have been described in
sand £ies [27]. During metacyclogenesis of L. major
promastigotes, the LPG undergoes extensive modi¢-
cations. These include an elongation of the molecule
due to an approximate doubling in the number of
oligosaccharide phosphate units expressed, and a
down-regulation in the number of side chain substi-
tutions expressing the terminal L1,3-linked galactose
in favor of side chains terminating in L1,3-linked
arabinopyranose [9,25]. The latter accounts for the
diminished binding of the lectins peanut agglutinin
and ricinus agglutinin to metacyclic promastigotes
previously observed [28,29]. More importantly, the
switch from terminal L1,3-linked galactose to L1,3-
linked arabinopyranose in the metacyclic LPG allows
the parasite to detach from the midgut and migrate
towards the insect’s mouthparts [9,25].
4.3. L. donovanii-sand £y interactions
Procyclic L. donovanii promastigotes express an
LPG (shown in Fig. 1) that di¡ers from L. major
by having no side chain substitutions [30]. The nat-
ural vector for L. donovanii is P. argentipes. It has
recently been found that L. donovanii attaches to P.
argentipes midguts via LPG cap structures which ter-
minate in L-linked galactose and K-linked mannose
residues [7]. While both of these non-reducing sugars
are required for high a⁄nity binding to the midguts,
there are very few details available about the putative
lectin(s). Similar to L. major, after several days in
which the bloodmeal is digested and excreted, L.
donovanii di¡erentiate to metacyclic forms and mi-
grate to the mouth parts of the insect. The molecular
basis for the detachment is accomplished by an alter-
ation in LPG structure. The metacyclic version of
LPG is approx. 2^2.5 times larger than the procyclic
form due to an approximate doubling in the number
of GalL1,4ManK1-PO4 repeat units [7]. However,
this is the only di¡erence that has been detected in
the primary structure of LPG, including the identical
L-linked galactose and K-linked mannose residues in
the terminal capping structure. So how is detachment
of the metacyclic L. donovanii achieved? The explan-
ation appears to be a masking of the terminal cap
sequence such that the L-linked galactose and K-
linked mannose residues are cryptic in metacyclic
LPG of L. donovanii [7]. Although the biochemical
reason for the cryptic nature of the cap is unknown,
the changes in the overall appearance of LPG can
account for the attachment/detachment process.
In summary, despite their considerable di¡erences
in structure, the LPGs from both L. major and L.
donovanii each undergo modi¢cations in size and ex-
pression of terminally exposed sugars. This evidently
may re£ect common molecular strategies for trans-
missible infections in the sand £y.
5. Glycoconjugates in vertebrate host-Leishmania
interactions
5.1. Interactions with host serum components
5.1.1. The complement system
Serum components, including molecules of the
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complement system, represent the ¢rst vertebrate
host defense molecules encountered by metacyclic
promastigotes following their inoculation into the
bloodstream. To succeed within the mammalian
host, Leishmania have evolved strategies both to re-
sist the lytic action of the complement system and
use it to gain access to a safe heaven, the inside of
a macrophage [31^33]. In this regard, numerous
studies have highlighted the importance of glycocon-
jugates in the Leishmania-complement interaction.
Sacks and colleagues evidenced a marked di¡erence
between non-infective (procyclic) and infective (meta-
cyclic) promastigotes with respect to serum sensitiv-
ity [34]. Indeed, non-infective (procyclic) promasti-
gotes of all Leishmania species are extremely
sensitive to fresh serum, whereas infectious (metacy-
clic) promastigotes display an increased resistance to
lysis. L. major procyclic promastigotes rapidly acti-
vate the complement cascade via the alternative
pathway, with deposition of covalently bound C3b
on the parasite surface. Deposition of C3b also oc-
curs on L. major metacyclic promastigotes, but these
infective forms are unable to activate the alternative
pathway in non-immune serum [35]. Further analyses
of this phenomenon revealed that resistance to lysis
is partly related to the developmentally regulated
modi¢cations of LPG [2,34]. The longer LPG mole-
cules expressed on metacyclic promastigotes may
contribute to their resistance to serum by preventing
access of the C5b-9 membrane attack complex to the
promastigote membrane. In addition, most of C5b-9
complexes are spontaneously released from the sur-
face of L. major metacyclic promastigotes, thereby
precluding their insertion into the membrane and
the subsequent death of the parasite [34]. L. donova-
nii promastigotes appear to avoid C5b-9 formation
and lysis by a distinct mechanism since C3bi, the
major form of C3 deposited on their surface, cannot
participate in the formation of a C5 convertase [36].
Analysis of lesion-derived L. major amastigotes re-
vealed that they activate complement and ¢x C3 [37],
which may facilitate their re-entry into macrophages
[38]. Interestingly, whereas L. mexicana amastigotes
can activate the alternative complement pathway and
¢x C3 in vitro [39], L. mexicana amastigotes isolated
from lesions contain no C3 at their surface [40].
These observations suggest that in lesions, comple-
ment ¢xation is prevented [40]. This phenomenon
might be related to the abundance of proteophospho-
glycan (PPG) which acts as a potent activator of the
complement cascade [41]. The numerous O-linked
phosphooligosaccharides capped by mannooligo-
saccharides on the PPG provide a ligand for the man-
nan-binding protein (MBP), which initiates one of
the pathways leading to complement activation. The
large quantities of PPG secreted by L. mexicana
amastigotes within the phagolysosomal compartment
may be released in the lesion when infected macro-
phages rupture [17], thereby leading to a local deple-
tion of complement. Complement activation by PPG,
away from the amastigote cell surface, may be neces-
sary for the pathology of L. mexicana infection, in-
cluding prevention of amastigote lysis and recruit-
ment of safe targets at the site of infection [41].
5.1.2. Other serum proteins
In addition to components of the complement sys-
tem, Leishmania promastigotes interact and bind to
other serum proteins to promote uptake by host
macrophages. Hence, the mannan-binding protein
(MBP) binds to mannose-terminating oligosaccha-
rides present in the cap structure of LPG and acts
as an activator of the complement cascade. There-
fore, binding of MBP at the surface of Leishmania
promastigotes provides an additional mechanism for
the formation of a C3 convertase and the subsequent
formation of C3b which participates in the attach-
ment to macrophages [42]. Phagocytosis of L. dono-
vanii promastigotes by human macrophages is also
enhanced following opsonization by the C-reactive
protein. This opsonin is a major acute phase protein
present in the serum during in£ammation, and spe-
ci¢cally binds to the Gal(L1,4)Man(K1-PO4) repeat-
ing units of L. donovanii LPG [43].
In summary, it is clear that both cell surface
(LPG) and secreted (PPG) glycoconjugates play a
key role in protecting Leishmania against non-speci¢c
host defense and in interacting with host serum com-
ponents.
6. Interactions with macrophages
6.1. Attachment
Because Leishmania infects primarily mononuclear
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phagocytic cells, attachment requires speci¢c recog-
nition molecules on the surfaces of both the parasite
and the host cell. Several Leishmania and macro-
phage cell surface molecules have been implicated
in the attachment process [44,45]. Although promas-
tigotes may bind to macrophages in the absence of
serum, presumably through the mannose receptor,
attachment normally occurs through the CR1, CR3
(Mac-1), and p150,95 [44]. Surface glycoconjugates
including LPG and gp63 play a major role in the
attachment process, as they represent the major ac-
ceptors for C3b and C3bi. Indeed, attachment of L.
major promastigotes to macrophages is inhibited by
the Fab fragment of an anti-L. major LPG antibody
[46]. However, phagocytosis of LPG-defective mu-
tants is similar or even superior to that of wild
type promastigotes [46^48]. It is possible that these
LPG-defective mutants enter macrophages via the
mannose/fucose receptor. Therefore, although the ex-
act contribution of LPG and gp63 in the attachment
process remains to be determined, it is clear that
using both CR1 and CR3 may favor the survival
of Leishmania promastigotes [32] since these recep-
tors promote phagocytosis without triggering the
oxidative burst [49]. Moreover, ligation of CR3 re-
sults in an inhibition of IL-12 production, a key
mediator of cell-mediated immunity [50,51].
6.2. Inside the macrophage
Subsequent to their attachment to macrophage re-
ceptors, promastigotes are internalized in a phago-
some. By interacting with various endocytic organ-
elles through a series of fusion and ¢ssion events [52],
the parasitophorous vacuole matures into a phagoly-
sosome in which the promastigote transforms and
multiplies as amastigote [53,54]. This implies that in
the mammalian host, the amastigote stage is adapted
to proliferate within the acidic and hydrolase-rich
environment of the phagolysosome. The molecular
mechanisms by which promastigotes e⁄ciently ini-
tiate infection, however, are poorly understood.
The requirement for LPG repeating units in this
process was shown by the demonstration that LPG
repeating unit-defective mutants are rapidly de-
stroyed following phagocytosis [46^48,55]. Without
LPG repeating units, promastigotes are thus unable
to withstand the conditions prevailing inside the
maturing parasitophorous vacuole. Because LPG
repeating units are also present on several secreted
glycoconjugates, including the secreted acid phos-
phatase (sAP), the phosphoglycan (PG), and the
proteophosphoglycan (PPG) (see above), a role for
all of these phosphoglycan-containing glycoconju-
gates must be considered in the Leishmania-macro-
phage interaction. In this regard, amastigotes prolif-
erate inside acidic, hydrolase-rich vacuoles, despite
the fact that they synthesize little or no detectable
cell surface LPG [56,57]. Secretion of large amounts
of PPG inside the phagolysosome by L. mexicana
amastigotes indicates that other phosphoglycan-con-
taining glycoconjugates may play a role during the
intracellular life cycle of the parasite [58].
The mechanisms by which the various virulence-
associated glycoconjugates enable Leishmania to ei-
ther withstand or turn o¡ the macrophage anti-mi-
crobicidal arsenal is an important area of research.
The contribution of LPG during the establishment of
infection by promastigotes has received a great deal
of attention. In this regard, LPG repeating units epi-
topes are present within minutes on the macrophage
surface at the immediate area of internalization of
the promastigote [61]. The epitopes are maximally
present in the macrophage membrane 1^2 days post
infection, and by 5^6 days, they are no longer detect-
able [59]. Thus, intracellular functions of LPG would
have to be attributed within the ¢rst several days
post infection when the parasite is most vulnerable.
The various properties of LPG and the other glyco-
conjugates with respect to intracellular parasitism are
reviewed in the next sections.
6.3. Inhibition of phagosome-endosome fusion by LPG
Whereas amastigotes reside inside acidic, hydro-
lase-rich phagolysosomes [1,53,54,60], L. donovanii
promastigotes inhibit phagosome-endosome fusion
during the early phase of infection [61]. The role of
LPG in this inhibition was evidenced by the obser-
vation that mutants defective in the synthesis of LPG
repeating units induced phagosomes that fuse exten-
sively with endocytic organelles, whereas wild type L.
donovanii promastigotes were present in non-fuso-
genic phagosomes [61]. Recent studies revealed that
while phagosomes containing wild type L. donovanii
promastigotes fail to acquire the late endocytic and
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lysosomal markers rab7 and LAMP1, LPG repeating
unit-defective mutant-containing phagosomes mature
rapidly into phagolysosomes by acquiring rab7 and
LAMP1 (Scianimanico et al. submitted for publica-
tion).
The mechanism by which LPG repeating units in-
hibit phagosome-endosome fusion may be related to
the demonstration that insertion of LPG in lipid bi-
layer membranes stabilizes the bilayer against the
formation of an inverted hexagonal structure, result-
ing in reduced fusogenic properties [62]. As a conse-
quence, LPG would give rise to an e¡ective steric
repulsion between phagosomal and endosomal mem-
branes or reduce the negative curvature strain in bi-
layers, increasing the energy barrier for forming
highly curved fusion intermediates, thereby prevent-
ing fusion. Truncated forms of LPG containing few
repeating units are ine¡ective in modifying the fuso-
genic properties of membranes [62]. This was con-
¢rmed recently when a mutant expressing truncated
LPG with three to ¢ve repeating units, compared to
the normal 15^30 units, was unable to inhibit phag-
osome-endosome fusion [61].
The extent to which the inhibition of phagosome-
endosome fusion contributes to the establishment of
infection by promastigotes remains to be determined.
Obviously, an impaired maturation of the para-
sitophorous vacuole may protect the promastigotes
from hydrolytic degradation and provide an environ-
ment propitious for their di¡erentiation into amasti-
gotes.
6.4. Expansion of L. mexicana phagolysosomes by
PPG
In contrast to L. donovanii, L. mexicana amasti-
gotes are taken up in a phagolysosome that expands
into a very large parasitophorous vacuole that can
occupy up to 70% of the host cell [63]. This phenom-
enon is still poorly understood, but may be related to
the abundant secretion of PPG into the parasito-
phorous vacuole. This hypothesis is based on the
demonstration that addition of puri¢ed amastigote-
derived PPG is highly e¡ective in inducing vacuoli-
zation of macrophages in vitro [58]. The role of such
a modi¢cation of the parasitophorous vacuole by
PPG remains to be elucidated.
6.5. Inhibition of hydrolytic enzymes by LPG
Proliferation within a phagolysosome entails the
ability to resist, inhibit, or inactivate host hydrolytic
enzymes. A role for LPG in protecting the parasite
from digestion by lysosomal enzymes was suggested
based on the observation that LPG coating of eryth-
rocytes signi¢cantly diminished their rate of cytolysis
by macrophages [64]. Although LPG may have pro-
vided a physical barrier against the hydrolytic en-
zymes present in the phagolysosome, the possibility
exists that LPG-coated erythrocytes prevented phag-
osome maturation, and hence, the acquisition of hy-
drolytic enzymes from endocytic organelles. Never-
theless, it is quite conceivable that the highly anionic
nature of LPG along with its unique GalL1,4Man
linkages in the repeating units may a¡ord protection
against degradative attack.
6.6. Chelation of calcium by LPG
Phagocytosis of LPG-coated erythrocytes caused
an increased in intracellular calcium levels, possibly
a consequence of calcium binding by LPG [64]. In-
deed, NMR studies revealed that calcium binds to
the LPG repeating units in the vicinity of the phos-
phate groups without perturbing the tridimensional
structure of the glycan [65]. Inasmuch as calcium
plays an important role in the regulation of various
cellular functions, its chelation by LPG may have
important implications with respect to the ability of
Leishmania parasites to survive within macrophages.
6.7. Modulation of macrophage signaling pathways
The expression of macrophage accessory and e¡ec-
tor functions is stringently regulated by multiple in-
tracellular signal transduction pathways. For an in-
tracellular parasite such as Leishmania, impairment
of host macrophage signaling pathways may repre-
sent a logical strategy to turn o¡ key microbicidal
functions. Indeed, Leishmania-infected macrophages
display an impaired responsiveness to interferon
(IFN)-Q, lipopolysaccharide and activators of protein
kinase C (PKC) [66,67].
PKC was ¢rst characterized as a Ca2-dependent
and phospholipid-dependent protein serine/threonine
kinase that requires diacylglycerol (DAG) for activ-
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ity. Subsequently, it has been established that PKC is
not a single entity, but rather a family of closely
related isoenzymes comprising at least 12 di¡erent
members. LPG is a potent inhibitor of puri¢ed rat
brain PKC activity in vitro (Ki6 1 WM) [68]. The
inhibition is selective, since LPG displays no e¡ect
on the catalytic fragment of PKC and the cAMP-
dependent protein kinase. Additional studies re-
vealed that the 1-O-alkylglycerol fragment exhibits
the most potent inhibitory activity, although the
phosphoglycan portion also causes signi¢cant inhib-
ition of puri¢ed PKC activity [69]. These results sug-
gest that LPG interacts with the regulatory domain
of PKC, which contains the binding sites for diacyl-
glycerol, calcium, and phospholipids. Another inter-
pretation of these in vitro data is that LPG perturbs
the insertion of PKC within the membrane, thereby
precluding its activation.
During infection, the parasite is present inside a
phagosome while PKC binds to the cytoplasmic
side of the plasma membrane. Despite the positions
of LPG and PKC on opposite sides of the mem-
brane, inhibition of PKC activity by LPG is still
observed [70]. Moreover, while 1 or 2% LPG mod-
estly inhibited binding of PKC to sucrose-loaded
vesicles, the presence of 5% LPG completely pre-
vented binding. A full-length LPG molecule is neces-
sary for maximal inhibition of PKC, which may be
the consequence of alterations in the physical proper-
ties of the membrane. Indeed, insertion of LPG in
lipid bilayers raises the TH (transition temperature in
which a bilayer forms hexagonal phase) of the mem-
brane and makes the rearrangement of proteins in
membranes more di⁄cult [62,70]. GIPLs, which rep-
resent the most abundant glycoconjugates of the
amastigote stage, also display an inhibitory activity
towards PKC [69]. The absence of repeating units
suggests that GIPLs and LPG use di¡erent mecha-
nisms to inhibit PKC activity.
By virtue of its pivotal role in transmembrane sig-
naling, PKC modulates a wide variety of cellular
functions. Consequently, treatment of macrophages
with puri¢ed LPG inhibited several PKC-dependent
events including induction of the respiratory burst, c-
fos gene expression, and chemotaxis [4,66]. Thus,
since macrophage-activating cytokines such as inter-
feron-Q and TNF-K act through PKC-dependent sig-
nal transduction pathways, impairment of PKC-de-
pendent gene expression would attenuate the impact
of external activating signals and therefore be bene-
¢cial for intracellular Leishmania.
6.8. Modulation of nitric oxide production
Macrophages express the inducible nitric oxide
synthase (iNOS) in response to various extracellular
signals, including IFN-Q, and bacterial lipopolysac-
charide (LPS) [71]. The iNOS enzyme is responsible
for the production of nitric oxide (NO), a molecule
with potent microbicidal activity, and is required for
resistance to Leishmania infection in mice [72]. Treat-
ment of macrophages with GIPLs inhibited synthesis
of NO in a time- and dose-dependent manner [73].
Consistently, leishmanicidal activity was reduced in
these GIPL-treated macrophages. While the whole
LPG molecule had no e¡ect on NO production, pre-
incubation of macrophages with the phosphoglycan
moiety (PG) of LPG potently inhibited iNOS expres-
sion [74]. Simultaneous addition of PG and interfer-
on-Q to macrophages, however, induced leishmanici-
dal activity and NO secretion [74]. Thus, the
production of NO, a key host defense molecule,
can be modulated by Leishmania glycoconjugates.
6.9. Scavenging of toxic oxygen metabolites
Because LPG repeating units are highly e¡ective in
scavenging hydroxyl radicals and superoxide anions,
it has been proposed that they may protect promas-
tigotes from these toxic oxygen metabolites generated
during the oxidative burst [47,75,76]. Thus, repeating
disaccharide phosphate unit-containing glycoconju-
gates may protect Leishmania from the oxidative
burst by at least two distinct mechanisms: (i) attenu-
ation of the PKC-mediated induction of the burst,
and (ii) scavenging of the cytocidal products of the
burst.
6.10. Suppression of macrophage IL-1L expression by
LPG
Among the consequences of Leishmania infection
on macrophage function, it has been reported that
agonist-induced production of IL-1, a key mediator
of immunity and in£ammation, is impaired [77,78].
Although the amastigotes molecule(s) responsible for
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this impairment remain to be identi¢ed, evidence was
provided that preincubation of macrophages with
LPG potently inhibited LPS-induced IL-1 produc-
tion [79]. Further analysis of this phenomenon re-
vealed that LPG inhibits IL-1L gene expression by
suppressing transcriptional activity, and involves a
unique sequence within the IL-1L promoter that
acts as a gene silencer. Interestingly, the whole
LPG molecule is required for this inhibitory activity,
which is agonist-speci¢c [80]. Suppression of tran-
scriptional activity by LPG may represent the ¢rst
example of a pathogen-derived molecule that medi-
ates its action by a unique promoter sequence acting
as a gene silencer [80].
6.11. LPG in HIV-1 pathogenesis
Epidemiological studies indicate that Leishmania is
an opportunistic pathogen in immunocompromised,
HIV-1-infected individuals [81,82]. The observation
that incubation of a human T cell line with puri¢ed
LPG induced HIV-1 LTR activity led to the sugges-
tion that Leishmania infection may contribute to the
pathogenesis of HIV infection [83]. On the other
hand, it has been demonstrated that LPG, a potent
inhibitor of viral membrane fusion [62], inhibited in a
dose-dependent manner HIV-1-induced syncytia for-
mation in CD4 T cells infected with syncytia-induc-
ing isolates of HIV-1, as well as viral replication in
CD4 T cells [84]. Thus, to reconcile these appar-
ently contradictory data, it can be envisioned that
while LPG may induce HIV-1 LTR activity, it may
also inhibit the subsequent steps leading to the
spread of the virus. Clearly, additional studies will
be necessary to determine to which extent LPG plays
a role in the pathogenesis of HIV-1 in Leishmania-
infected individuals.
6.12. Concluding remark
The remarkably large number of functions that
have been proposed for LPG and related glycocon-
jugates is truly astounding. These functions can be
attributed to the uniqueness of the distinct carbohy-
drate and lipid domains of these glycoconjugates.
Since many of these proposed functions contribute
to the Leishmania pathogenesis, LPG and related
glycoconjugates may prove ultimately to be ideal tar-
gets of chemotherapeutic intervention.
References
[1] J. Alexander, D.G. Russell, Adv. Parasitol. 31 (1992) 175^
254.
[2] D.L. Sacks, Exp. Parasitol. 69 (1989) 100^103.
[3] D. Zilberstein, M. Shapira, Annu. Rev. Microbiol. 48 (1994)
449^470.
[4] S.J. Turco, A. Descoteaux, Annu. Rev. Microbiol. 46 (1992)
65^94.
[5] M.J. McConville, M.A.J. Ferguson, Biochem. J. 294 (1993)
305^324.
[6] S.M. Beverley, S.J. Turco, Trends Microbiol. 6 (1998) 35^
40.
[7] D.L. Sacks, P.F.P. Pimenta, M.J. McConville, P. Schneider,
S.J. Turco, J. Exp. Med. 181 (1995) 685^697.
[8] D.L. Sacks, T.N. Brodin, S.J. Turco, Mol. Biochem. Para-
sitol. 42 (1990) 225^233.
[9] M.J. McConville, S.J. Turco, M.A.J. Ferguson, D.L. Sacks,
EMBO J. 11 (1992) 3593^3600.
[10] P.F.P. Pimenta, E.M.B. Saraiva, E. Rowton, G.B. Modi,
L.A. Garraway, S.M. Beverley, S.J. Turco, D.L. Sacks,
Proc. Natl. Acad. Sci. USA 91 (1994) 9155^9159.
[11] S.J. Turco, D.L. Sacks, Mol. Biochem. Parasitol. 45 (1991)
91^100.
[12] T.A. Glaser, S.F. Moody, E. Handman, A. Bacic, T.W. Spit-
hill, Mol. Biochem. Parasitol. 45 (1991) 337^344.
[13] S.F. Moody, E. Handman, M.J. McConville, A. Bacic,
J. Biol. Chem. 268 (1993) 18457^18466.
[14] B.J. Mengeling, S.M. Beverley, S.J. Turco, Glycobiology 7
(1997) 873^880.
[15] P. Schneider, M.A.J. Ferguson, M.J. McConville, A. Meh-
lert, S.W. Homans, C. Bordier, J. Biol. Chem. 265 (1990)
16955^16964.
[16] T. Ilg, Y.-D. Stierhof, M. Wiese, M.J. McConville, P. Over-
ath, Parasitology 108 (Suppl.) (1994) S63^S71.
[17] T. Ilg, Y.-D. Stierhof, M.J. McConville, P. Overath, Eur. J.
Cell Biol. 66 (1995) 205^215.
[18] T. Ilg, Y.D. Stierhof, D. Craik, R. Simpson, E. Handman,
A. Bacic, J. Biol. Chem. 271 (1996) 21583^21596.
[19] T. Ilg, D. Craik, G. Currie, G. Multhaup, A. Bacic, J. Biol.
Chem. 273 (1998) 13509^13523.
[20] K.D. Greis, S.J. Turco, J.R. Thomas, M.J. McConville,
S.W. Homans, M.A.J. Ferguson, J. Biol. Chem. 267 (1992)
5876^5881.
[21] M.J. McConville, T.A.C. Collidge, M.A.J. Ferguson, P.
Schneider, J. Biol. Chem. 268 (1993) 15595^15604.
[22] Y. Schlein, L.F. Schnur, R.L. Jacobson, Trans. R. Soc.
Trop. Med. Hyg. 84 (1990) 353^355.
[23] M.J. McConville, A. Bacic, G.F. Mitchell, E. Handman,
Proc. Natl. Acad. Sci. USA 84 (1987) 8941^8945.
BBADIS 61870 14-9-99
A. Descoteaux, S.J. Turco / Biochimica et Biophysica Acta 1455 (1999) 341^352350
[24] K. Ng, E. Handman, A. Bacic, Glycobiology 4 (1994) 845^
853.
[25] P.F.P. Pimenta, S.J. Turco, M.J. McConville, P.G. Lawyer,
P.V. Perkins, D.L. Sacks, Science 256 (1992) 1812^1815.
[26] B.A. Butcher, S.J. Turco, B.A. Hilty, P.F. Pimenta, M. Pan-
unzio, D.L. Sacks, J. Biol. Chem. 271 (1996) 20573^
20579.
[27] K.R. Wallbanks, G.A. Ingram, D.H. Molyneux, Trop. Med.
Parasitol. 37 (1986) 409^413.
[28] D.L. Sacks, P.V. Perkins, Science 223 (1984) 1417^1419.
[29] M.K. Howard, G. Sayers, M.M. Miles, Exp. Parasitol. 64
(1987) 147^156.
[30] J.R. Thomas, M.J. McConville, J.E. Thomas-Oates, S.W.
Homans, M.A.J. Ferguson, P.A.J. Gorin, K.D. Greis, S.J.
Turco, J. Biol. Chem. 267 (1992) 6829^6833.
[31] R.P. Da Silva, B.F. Hall, K.A. Joiner, D.L. Sacks, J. Im-
munol. 143 (1989) 617^622.
[32] D.M. Mosser, P.J. Edelson, Nature 327 (1987) 329^331.
[33] D.M. Mosser, P.J. Edelson, J. Immunol. 135 (1985) 2785^
2789.
[34] S.M. Puentes, R.P. Da Silva, D.L. Sacks, C.H. Hammer,
K.A. Joiner, J. Immunol. 145 (1990) 4311^4316.
[35] S.M. Puentes, D.L. Sacks, R.P. da Silva, K.A. Joiner, J. Exp.
Med. 167 (1988) 887^902.
[36] S.M. Puentes, D.M. Dwyer, P.A. Bates, K.A. Joiner, J. Im-
munol. 143 (1989) 3743^3749.
[37] M. Kelleher, S.F. Moody, P. Mirabile, A.H. Osborn, A.
Bacic, E. Handman, Infect. Immun. 63 (1995) 43^50.
[38] R.A. Guy, M. Belosevic, Infect. Immun. 61 (1993) 1553^
1558.
[39] D.M. Mosser, J.F. Wedgwood, P.J. Edelson, J. Immunol.
134 (1985) 4128^4131.
[40] C. Peters, T. Aebischer, Y.D. Stierhof, M. Fuchs, P. Over-
ath, J. Cell Sci. 108 (1995) 3715^3724.
[41] C. Peters, M. Kawakami, M. Kaul, T. Ilg, P. Overath, T.
Aebischer, Eur. J. Immunol. 27 (1997) 2666^2672.
[42] P.J. Green, T. Feizi, M.S. Stoll, S. Thiel, A. Prescott,
M.J. McConville, Mol. Biochem. Parasitol. 66 (1994) 319^
328.
[43] F.J. Culley, R.A. Harris, P.M. Kaye, K.P. McAdam, J.G.
Raynes, J. Immunol. 156 (1996) 4691^4696.
[44] D.M. Mosser, L.A. Rosenthal, Semin. Cell Biol. 4 (1993)
315^322.
[45] E. Handman, J.W. Goding, EMBO J. 4 (1985) 329^336.
[46] M. Elhay, M. Kelleher, A. Bacic, M.J. McConville, D.L.
Tolson, T.W. Pearson, E. Handman, Mol. Biochem. Para-
sitol. 40 (1990) 255^267.
[47] T.B. McNeely, S.J. Turco, J. Immunol. 144 (1990) 2745^
2750.
[48] A. Descoteaux, G. Matlashewski, S.J. Turco, J. Immunol.
149 (1992) 3008^3015.
[49] S.D. Wright, S.C. Silverstein, J. Exp. Med. 158 (1983) 2016^
2023.
[50] T. Marth, B.L. Kelsall, J. Exp. Med. 185 (1997) 1987^
1995.
[51] F.S. Sutterwala, G.J. Noel, R. Clynes, D.M. Mosser, J. Exp.
Med. 185 (1997) 1977^1985.
[52] M. Desjardins, Trends Cell Biol. 5 (1995) 183^186.
[53] J. Alexander, K. Vickerman, J. Protozool. 22 (1975) 502^
508.
[54] K.P. Chang, D.M. Dwyer, Science 193 (1976) 678^680.
[55] E. Handman, L.F. Schnur, T.W. Spithill, G.F. Mitchell,
J. Immunol. 137 (1986) 3608^3613.
[56] M.J. McConville, J.M. Blackwell, J. Biol. Chem. 266 (1991)
15170^15179.
[57] V. Bahr, Y.D. Stierhof, T. Ilg, M. Demar, M. Quinten, P.
Overath, Mol. Biochem. Parasitol. 58 (1993) 107^121.
[58] C. Peters, Y.D. Stierhof, T. Ilg, Infect. Immun. 65 (1997)
783^786.
[59] D.L. Tolson, S.J. Turco, T.W. Pearson, Infect. Immun. 58
(1990) 3500^3507.
[60] J.C. Antoine, E. Prina, C. Jouanne, P. Bongrand, Infect.
Immun. 58 (1990) 779^787.
[61] M. Desjardins, A. Descoteaux, J. Exp. Med. 185 (1997)
2061^2068.
[62] L. Miao, A. Sta¡ord, S. Nir, S.J. Turco, T.D. Flanagan,
R.M. Epand, Biochemistry 34 (1995) 4676^4683.
[63] J.C. Antoine, Pathol. Biol. 43 (1995) 215^223.
[64] Y. Eilam, J. El-On, D.T. Spira, Exp. Parasitol. 59 (1985)
161^168.
[65] S.W. Homans, A. Mehlert, S.J. Turco, Biochemistry 31
(1992) 654^661.
[66] A. Descoteaux, S.J. Turco, Parasitol. Today 9 (1993) 468^
471.
[67] N.E. Reiner, Immunol. Today 15 (1994) 374^381.
[68] T.B. McNeely, S.J. Turco, Biochem. Biophys. Res. Com-
mun. 148 (1987) 653^657.
[69] T.B. McNeely, G. Rosen, M.V. Londner, S.J. Turco, Bio-
chem. J. 259 (1989) 601^604.
[70] J.R. Giorgione, S.J. Turco, R.M. Epand, Proc. Natl. Acad.
Sci. USA 93 (1996) 11634^11639.
[71] C. Nathan, Q.W. Xie, J. Biol. Chem. 269 (1994) 13725^
13728.
[72] X.Q. Wei, I.G. Charles, A. Smith, J. Ure, G.J. Feng, F.P.
Huang, D. Xu, W. Muller, S. Moncada, F.Y. Liew, Nature
375 (1995) 408^411.
[73] L. Proudfoot, C.A. O’Donnell, F.Y. Liew, Eur. J. Immunol.
25 (1995) 745^750.
[74] L. Proudfoot, A.V. Nikolaev, G.J. Feng, W.Q. Wei, M.A.
Ferguson, J.S. Brimacombe, F.Y. Liew, Proc. Natl. Acad.
Sci. USA 93 (1996) 10984^10989.
[75] J. Chan, T. Fujiwara, P. Brennan, M. McNeil, S.J. Turco,
J.C. Sibille, M. Snapper, P. Aisen, B.R. Bloom, Proc. Natl.
Acad. Sci. USA 86 (1989) 2453^2457.
[76] J. El-On, M. Zvillich, I. Sarov, Parasite Immunol. 12 (1990)
285^295.
[77] N.E. Reiner, J. Immunol. 138 (1987) 1919^1925.
[78] N.E. Reiner, W. Ng, C.B. Wilson, W.R. McMaster, S.K.
Burchett, J. Clin. Invest. 85 (1990) 1914^1924.
BBADIS 61870 14-9-99
A. Descoteaux, S.J. Turco / Biochimica et Biophysica Acta 1455 (1999) 341^352 351
[79] S. Frankenburg, V. Leibovici, N. Mansbach, S.J. Turco, G.
Rosen, J. Immunol. 145 (1990) 4284^4289.
[80] D.E. Hatzigeorgiou, J. Geng, B. Zhu, Y. Zhang, K. Liu,
W.N. Rom, M.J. Fenton, S.J. Turco, J.L. Ho, Proc. Natl.
Acad. Sci. USA 93 (1996) 14708^14713.
[81] C. Montalban, J.L. Calleja, A. Erice, F. Laguna, B. Clotet,
D. Podzamczer, J. Cobo, J. Mallolas, M. Yebra, A. Gallego,
J. Infect. 21 (1990) 261^270.
[82] A. Cabie, S. Matheron, A. Lepretre, O. Bouchaud, A.M.
Deluol, J.P. Coulaud, Presse Med. 21 (1992) 1658^1662.
[83] R. Bernier, B. Barbeau, M.J. Tremblay, M. Olivier, J. Im-
munol. 160 (1998) 2881^2888.
[84] M.D. Easterbrook, M.H. Levy, A.M. Gomez, S.J. Turco,
R.M. Epand, K.L. Rosenthal, J. Acquired Immune De¢c.
Syndr. Hum. Retrovirol. 10 (1995) 496^505.
BBADIS 61870 14-9-99
A. Descoteaux, S.J. Turco / Biochimica et Biophysica Acta 1455 (1999) 341^352352
